Altiratinib
Cat. No.：YN380183
CAS No. ：1345847-93-9
| 产品名称: | Altiratinib |
| CAS No.: | 1345847-93-9 |
| Chemical Name: | N-[4-[[2-[(cyclopropylcarbonyl)amino]-4-pyridinyl]oxy]-2,5-difluorophenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide |
| Synonyms: | DCC-2701 |
| 分子量: | 510.46 |
| 分子式: | C₂₆H₂₁F₃N₄O₄ |
| SMILES: | O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC(F)=C(OC4=CC(NC(C5CC5)=O)=NC=C4)C=C3F |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Altiratinib (DCC-2701) 是多靶点激酶抑制剂，抑制MET，TIE2，VEGFR2，FLT3，Trk1，Trk2和Trk3的IC50值分别为2.7，8，9.2，9.3，0.85，4.6，0.83 nM。 |
| IC50和靶点: | [{name:"VEGFR2:9.2 nM (IC50)"},{name: "Trk1:0.85 nM (IC50)"},{name: "Trk2:4.6 nM (IC50)"},{name: "Trk3:0.93 nM (IC50)"},{name: "MET:2.7 nM (IC50)"},{name: "TIE2:8 nM (IC50)"},{name: "FLT3:9.3 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Smith, B.D., Kaufman, M.D., Leary, C.B., et al.Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2Mol. Cancer Ther.14(9),2023-2034(2015)
Piao, Y., Park, S.Y., Henry, V., et al.Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse modelsNeuro. Oncol.18(9),1230-1241(2016)
